Skip to content
← Full study record

NCT00465985 · MORE INFO

Limitations, agreements, and source contact

Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome · Source last updated 2017-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
The outcomes for this study were reported in separate tables for each period. The SAE and AEs were reported in all in one table.
point Of Contact
organization
Novartis Pharmaceuticals
phone
862-778-8300
title
Study Director
Complete source fields
certain Agreement
other Details
The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
The outcomes for this study were reported in separate tables for each period. The SAE and AEs were reported in all in one table.
point Of Contact
organization
Novartis Pharmaceuticals
phone
862-778-8300
title
Study Director

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice